All In Biotech

Investigational drug · Phase 2

AP1189

Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Rheumatoid Arthritis (RA), Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy, Severe Proteinuria Due to Idiopathic Membranous Nephropathy.

Phase 2

Last checked: Nov 19, 2026Latest source record: Jul 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

3

3 still active

All registered trials

6

Any phase or sponsor naming "AP1189"

First trial start

2020

Aug 31, 2020

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "AP1189", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Rheumatoid Arthritis (RA)
  • Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy
  • Severe Proteinuria Due to Idiopathic Membranous Nephropathy
  • Respiratory Viral Infection

Approved drugs for the same conditions: Rheumatoid arthritis · Immunology and inflammation · Infectious disease and vaccines · Rare and genetic disease · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "AP1189" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 4 on PubMed

Also in development for Rheumatoid Arthritis (RA)

  • TLL-018Phase 38 trials

    Hangzhou Highlightll Pharmaceutical Co., Ltd · Chronic Spontaneous Urticaria (CSU), Rheumatoid Arthritis, Chronic Spontaneous Urticaria

  • Beijing VDJBio Co., LTD. · Anti IL-6R, Idiopathic Multicentric Castleman's Disease, Castleman's Disease, Multicentric

  • mAbxience Research S.L. · Rheumatoid Arthritis (RA)

  • QLS12010Phase 23 trials

    Qilu Pharmaceutical Co., Ltd. · Adults With Moderate-to-severe Hidradenitis Suppurativa, Moderate-to-severe Atopic Dermatitis, Rheumatoid Arthritis (RA)

  • JAB-8263Phase 22 trials

    Jacobio Pharmaceuticals Co., Ltd. · Rheumatoid Arthritis (RA), NSCLC, SCLC

  • TollB-001Phase 22 trials

    Toll Biotech Co. Ltd. (Beijing) · Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc)

  • FT839Phase 21 trial

    Fate Therapeutics · ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Rheumatoid Arthritis (RA)

  • QEL-005Phase 21 trial

    Quell Therapeutics Limited · Diffuse Cutaneous Systemic Sclerosis, Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.